Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Antidepressant Suicide Data To Be Evaluated For FDA By Columbia University

Executive Summary

Columbia University will coordinate a review of pediatric antidepressant suicidal event data for FDA

You may also be interested in...



As FDA Suicidality Reviews Become More Common, Firms Move Into C-CASA

FDA's review of anticonvulsant drugs for suicidality risks suggests that firms should reevaluate their clinical development strategies to anticipate a growing need for such data

As FDA Suicidality Reviews Become More Common, Firms Move Into C-CASA

FDA's review of anticonvulsant drugs for suicidality risks suggests that firms should reevaluate their clinical development strategies to anticipate a growing need for such data

Antidepressant Fallout Includes Change In FDA Pediatric Study Procedure

Studies conducted under the Best Pharmaceuticals for Children Act will be included in labeling, FDA Office of Medical Policy Director Robert Temple, MD, told the House Energy & Commerce/Oversight Subcommittee Sept. 23

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS043194

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel